Purchase this article with an account.
Teresa Rolle, Rachele R Penna, Laura Dallorto, Fiamma Campana, Luigia Scudeller, Sara Lanteri, Gemma C Rossi; Six months study on signs and symptoms of polyquad preserved travoprost/timolol fixed combination on previously treated glaucoma patients.. Invest. Ophthalmol. Vis. Sci. 2014;55(13):2916. doi: https://doi.org/.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To assess usefulness and tolerability of switching glaucoma patients to the fixed combination Travoprost 0.004%/Timolol 0.5% with polyquad (PQ-TTFC); to record effects on tear film break-up time (TF-BUT) and on quality of life (OSDI).
Multicenter, observational cohort, 6 month study. 50 patients on concomitant Timolol 0.5% (twice a day) and Dorzolamide (twice a day) or Timolol and Latanoptost (once a day) (BAK-preserved) were switched to PQ-TTFC (evening dosage). IOP, TFBUT and AEs were recorded and all patients completed the OSDI questionnaire at baseline and after 6 months. All analysis refers to right eye; left eye’s data are similar.
Median age was 70 [63-73] years, women were 54.9% of the sample. IOP significantly decreased (from 18 [16-21] to 15 [12-17] mmHg) after substitution (p<0,001). At baseline 31.4% of patients presented an IOP <18mmHg, the percentage increased to 80% of subjects at 6 months (p<0.001). TF-BUT improved of 2.7±1.9 sec (from 7 [5-8] to 10 [9-11] sec, p<0.001). Only one patient discontinued the new therapy due to periocular skin pigmentation. Quality of life improved from 28 (moderate) to 19 (mild) (p<0.001).
PQ-TTFC appeared useful in this selected population: patients who underwent a regimen modification to PQ-TTFC obtained further reduction in IOP; improvement in ocular surface status with no exposition to BAK toxicity; and reported a better quality of life perception. The low discontinuation’s rate at 6 months indicates a good tolerability profile.
This PDF is available to Subscribers Only